about
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerAberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast CancerDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerAnalysis of different HER-2 mutations in breast cancer progression and drug resistanceReceptor tyrosine kinases in the nucleusEGFR/HER-targeted therapeutics in ovarian cancerHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsA novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancersCorrelation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerHER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Trastuzumab emtansine: mechanisms of action and drug resistanceInterference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.Therapeutic targeting of integrin αvβ6 in breast cancer.Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers.Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenograftsEffect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.BKCa channel inhibitor modulates the tumorigenic ability of hormone-independent breast cancer cells via the Wnt pathwayMechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.CX3CL1 promotes breast cancer via transactivation of the EGF pathwayMechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerMeasurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerThe Therapeutic Challenge of Targeting HER2 in Endometrial CancerProteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceActivating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpressionNeratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseMechanisms of acquired resistance to targeted cancer therapies.Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues.Biomarkers of drugs targeting HER-family signalling in cancer.Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.
P2860
Q26752780-AD4F61F8-A651-4EBE-8B79-62C019C06C76Q26764879-669B39E1-1AE0-4AC2-8D7E-232AEC2B418FQ26772969-CA18C50C-9F31-4717-9B21-BAA6D4711BF5Q26773907-14201D0A-E294-4E9A-B3EA-0DB2DF2B5AFEQ26785612-AD153A1F-A969-481F-BB42-855D868187E4Q26797471-51C964A0-FBE8-4F5C-929A-6A6A44B5E907Q26830216-E0945581-663B-41B3-9AFE-937A4FC3D1DEQ26863231-6F1255C0-85EE-4593-83C4-98C287C04EFFQ28078111-17631CAF-549A-44FC-8FC2-9F64B647918DQ28485310-5141FC75-79C0-478D-BBD6-22D2E2761E59Q28728701-4B38242C-5642-4086-A495-31043C8AB97FQ33737278-B5EC5B13-0590-41E6-87B6-70F9ADFC280DQ33759627-0B608F0A-9358-48EC-AC8A-4C0BBCF3B28EQ33966430-8A1DD385-100B-48A4-AF80-EE5551F3AE58Q34120685-F7EC58F1-89F9-4AB3-9103-E0F5A53134FAQ34308692-E33019D5-AC72-4968-8C1D-7ACFB98E0CA4Q34318275-E736A636-6170-4B92-BFD6-AD1C14B889F4Q34714574-00CCA842-9321-4B73-941C-A9C414603E6AQ34736064-384DD067-76F1-45B6-B566-ED2413303AB2Q35012494-8761A2DF-0660-405A-8471-AF3C6D0BAB0AQ35624814-34B129E7-34CB-466B-A0A1-5D7506F1CC39Q35945009-1E4D3E90-56D4-4875-8C1B-D860B12ADEBBQ35977527-6C448AFD-AC15-432A-B892-A968EB3830E3Q36009610-5B4E4212-B512-45B2-A9EE-2150CC14C1BFQ36064908-76316F65-F56D-4772-852B-D805BD425A06Q36064912-4D69DCE5-780D-4D03-A523-68D8B5ECDB8EQ36113481-B1066C73-5771-49D7-9DEA-097A6F5133FFQ36250585-188BDDCE-3F0C-4210-81B4-73F27A2097A9Q36785721-3431E8A5-5B67-42FF-AADA-64715E7FB32CQ36810717-5A696320-CB83-4995-A04A-9B9A3C6696EEQ37341891-41A14393-A284-4E50-83FD-712E95D61AE9Q37381579-DDD6A3AE-E07D-4168-9B99-5A13B4AD4B2EQ37444430-E03C902F-D6AB-48F7-8A94-B102161070AAQ37447938-F149A80C-ED0F-4126-AE63-941B513FF887Q37722926-C68DE771-3678-44F0-B5AB-633735FB2ECEQ38034816-F3E17D4D-C446-4CE3-B598-D52BC46E4038Q38111772-EEC0103F-A280-47E0-9A79-3C90DBFE5856Q38150774-89BDE822-2F44-4291-B782-4FFDB20F06E4Q38253835-84E0957E-A653-47B0-8C9D-0FFAF02521A9Q38673589-38A721F5-5E55-44ED-882C-CA851008E6A2
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
p95HER2 and breast cancer.
@en
p95HER2 and breast cancer.
@nl
type
label
p95HER2 and breast cancer.
@en
p95HER2 and breast cancer.
@nl
prefLabel
p95HER2 and breast cancer.
@en
p95HER2 and breast cancer.
@nl
P2093
P1433
P1476
p95HER2 and breast cancer.
@en
P2093
Joaquín Arribas
Josep Lluís Parra-Palau
José Baselga
Kim Pedersen
P304
P356
10.1158/0008-5472.CAN-10-3795
P407
P577
2011-02-22T00:00:00Z